Publisher Correction: Cardiovascular Events Among Men With Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-Analysis, and Network Meta-Analysis (Prostate Cancer and Prostatic Diseases, (2025), 28, 2, (298-308), 10.1038/S41391-024-00886-0) Publisher Pubmed



A Matsukawa AKIHIRO ; T Yanagisawa TAKAFUMI ; M Kardoust Parizi MEHDI ; Ea Laukhtina Ekaterina A ; J Klemm JAKOB ; T Fazekas TAMAS ; K Mori KEIICHIRO ; S Kimura SHOJI ; A Briganti ALBERTO ; G Ploussard GUILLAUME
Source: Prostate Cancer and Prostatic Diseases Published:2025

Abstract

Correction to: Prostate Cancer and Prostatic Diseaseshttps://doi.org/10.1038/s41391-024-00886-0, published online 5 September 2024 In Table 3 of this article, the data in column 1–7 were mistakenly listed. Please see the corrected table below. Table 3 Summary of NMA on cardiovascular events with ARSIs. (Table presented.) Cardiac disorder Heart failure IHD AF Hypertension Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3 Data summary of included studies 5 studie 5 comparisons 5786 patients 7 studie 7 comparisons 6546 patients 10 studies 10 comparisons 11,424 patients 8 studies 8 comparisons 9157 patients 6 studies 6 comparisons 7215 patients 5 studies 5 comparisons 5820 patients 11 studies 11 comparisons 9765 patients 9 studies 9 comparisons 7,381 patients 23 studies 23 comparisons 17,819 patients 20 studies 20 comparisons 16,507 patients SOC RR (95% CI) Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. SUCRA value 91% 90% 80% 85% 99% 86% 85% 88% 76% 75% Abi RR (95% CI) 1.48 (1.05–2.08) 2.40 (1.42–4.06) 1.77 (0.52–6.02) 2.93 (0.51–16.86) NA NA 1.51 (0.96–2.38) 2.07 (0.85–5.08) 1.70 (1.32–2.19) 2.19 (1.77–2.70) SUCRA value 13% 2% 37% 37% 27% 37% 26% 19% Apa RR (95% CI) NA NA 1.33 (0.42–4.17) 1.92 (0.26–14.46) 2.32 (0.97–5.54) 2.08 (0.46–9.41) 1.31 (0.63–2.71) 1.55 (0.45–5.26) 0.88 (0.53–1.46) 0.63 (0.31–1.29) SUCRA value 54% 53% 25% 32% 47% 59% 85% 96% Dar RR (95% CI) NA NA 2.09 (0.77–5.66) 4.65 (0.25–88.20) NA NA NA NA 1.19 (0.57–2.49) 1.47 (0.77–2.82) SUCRA value 27% 30% 57% 49% Enz RR (95% CI) 1.24 (0.80–1.92) 1.25 (0.73–2.13) 1.40 (0.62–3.16) 2.32 (0.74–7.28) 2.38 (1.32–4.30) 2.02 (0.62–6.63) 1.37 (0.74–2.53) 3.17 (1.05–9.58) 2.08 (1.61–2.70) 2.30 (1.82–2.92) SUCRA value 46% 58% 53% 44% 26% 31% 41% 15% 5% 12% Ranking SOC>Enz>Abi SOC>Enz>Abi SOC>Apa>Enz>Abi>Dar SOC>Apa>Enz>Abi>Dar SOC>Enz>Apa SOC>Apa>Enz SOC>Apa>Enz>Abi SOC>Apa>Abi>Enz Apa>SOC>Dar>Abi>Enz Apa>SOC>Dar>Abi>Enz Cochran’s Q test p = 0.03 p = 0.2 p = 0.9 p = 0.9 p = 0.01 p < 0.01 p = 0.4 p > 0.9 p < 0.001 p = 0.5 NMA network meta-analysis, RR risk ratio, CI Confidence Interval, IHD ischemic heart disease, AF atrial fibrillation, Ref reference, NA not available, SOC standard of care, Abi abiraterone, Enz enzalutamide, Apa apalutamide, Dar darolutamide. © 2025 Elsevier B.V., All rights reserved.